Katarina Zimmer | Apr 4, 2019 | 4 min read
Breast cancer researcher and oncologist Nancy Davidson discusses what we’ve learned from the first wave of epigenetic trials for breast cancer, and what challenges lie ahead before such therapies reach the clinic.